New LaunchNov 4, 2026, 04:05 PM
Revolution Medicines Launches RASONQUE; EU Approval Recommended; Q3 Revenue $198M
AI Summary
Revolution Medicines announced the U.S. FDA approval and commercial launch of RASONQUE (daraxonrasib) for adult patients with metastatic pancreatic cancer. The drug generated $197.6 million in net product revenue in its first partial quarter. Additionally, the company received a positive CHMP opinion recommending marketing authorization for daraxonrasib in the European Union. Revolution Medicines reported a net loss of $407.5 million for the third quarter of 2026, with cash reserves of $3.7 billion. The company also highlighted progress in its clinical pipeline, including FDA Breakthrough Therapy Designation for a combination therapy.
Key Highlights
- Revolution Medicines launched RASONQUE (daraxonrasib) in the U.S. on August 26, 2026, for metastatic pancreatic cancer.
- RASONQUE generated $197.6 million in net product revenue in its first partial quarter (approx. 5 weeks).
- Over 5,000 unique patients received commercial RASONQUE in the U.S. by September 30, 2026.
- CHMP recommended marketing authorization for daraxonrasib in the European Union for metastatic pancreatic cancer.
- Company reported Q3 2026 net loss of $407.5 million, compared to $305.2 million in Q3 2025.
- Cash, cash equivalents, and marketable securities stood at $3.7 billion as of September 30, 2026.
- FDA granted Breakthrough Therapy Designation for daraxonrasib in combination with gemcitabine and nab-paclitaxel for treatment-naïve metastatic pancreatic cancer.
Price Impact
More from RVMD